Diagnostic Proteomics

Proteomics for Biological Discovery

Volumn , Issue , 2006, Pages 247-276

  Prieto, Darue A ^a   Issaq, Haleem J ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Diagnostic proteomics; Proteomic pattern diagnostics using SELDI TOF MS; Proteomic patterns in disease diagnosis concept

Indexed keywords

EID: 84891286615     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470007745.ch13     Document Type: Chapter

References (88)

1. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL Jr. 2002. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia in healthy men. Cancer Res 62:3609-3614.
2. American Cancer Society, Cancer Statistics. 2004. Available from http://www.cancer.org/docroot/STT/stt_0.asphtml. Accessed December 1, 2004.
3. Anderson NL, Anderson NG. 2002. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845-867.
4. Banez LL, Prasanna P, Sun L, Ali A, Zou Z, Adam BL, McLeod DG, Moul JW, Srivastava S. 2003. Diagnostic potential of serum proteomic patterns in prostate cancer. J Urol 170:442-446.
5. Barzaghi D, Isbister JD, Lauer KP, Born TL. 2004. Use of surface-enhanced laser desorption/ionization-time of flight to explore bacterial proteomes. Proteomics 4:2624-2628.
6. Bergman AC, Benjamin T, Alaiya A, Waltham M, Sakaguchi K, Franzen B, Linder S, Bergman T, Auer G, Appella E, Wirth PJ, Jornvall H. 2000. Identification of gelseparated tumor marker proteins by mass spectrometry. Electrophoresis 21:679-686.
7. Bock C, Coleman M, Collins B, Davis J, Foulds G, Gold L, Greef C, Heil J, Heilig JS, Hicke B, Nelson-Hurst M, Husar GM, Miller D, Ostroff R, Petach H, Schneider D, Vant-Hull B, Waugh S, Weiss A, Wilcox SK, Zichi D. 2004. Photoaptamer arrays applied to multiplexed proteomic analysis. Proteomics 4:609-618.
8. Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P, Hochstrasser DF, Sanchez J-C. 2003. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3:1486-1494.
9. Cash P, Kroll JS. 2003. Protein characterization by two-dimensional gel electrophoresis. Methods Mol Med 71:101-118.
10. Chaurand P, Sanders ME, Jensen RA, Caprioli RM. 2004a. Proteomics in diagnostic pathology: profiling and imaging proteins directly in tissue sections. Am J Pathol 165:1057-1068.
11. Chaurand P, Schwartz SA, Caprioli RM. 2004b. Assessing protein patterns in disease using imaging mass spectrometry. J Proteome Res 3:245-252.
12. Conrads TP, Veenstra TD. 2004. The utility of proteomic patterns for the diagnosis of cancer. Curr Drug Targets 4:41-50.
13. Conrads TP, Fusaro VA, Ross S, Johann D, Rajapakse V, Hitt BA, Steinberg SM, Kohn EC, Fishman DA, Whitely G, Barrett JC, Liotta LA, Petricoin EF III, Veenstra TD. 2004a. High resolution serum proteomic features for ovarian cancer detection. Endocr Relat Cancer 11:163-178.
14. Conrads TP, Hood BL, Issaq HJ, Veenstra TD. 2004b. Proteomic patterns as a diagnostic tool for early-stage cancer. Mol Diagn 8:77-85.
15. DiMagno EP, Reber HA, Tempero MA. 1999. Epidemiology, diagnosis and treatment of pancreatic ductal adenocarcinoma. Gastroenterology 117:1463-1484.
16. Fels LM, Buschmann T, Meuer J, Reymond MA, Lamer S, Rocken C, Ebert MPA. 2003. Proteome analysis for the identification of tumor-associated biomarkers in gastrointestinal cancer. Dig Dis 21:292-298.
17. Govorukhina NI, Keizer-Gunnink A, van der Zee AGJ, de Jong SH, de Bruijn'and WA, Bischoff WA. 2003. Sample preparation of human serum for the analysis of tumor markers: comparison of different approaches for albumin and γ-globulin depletion. J Chromatogr A 1009:171-178.
18. Hamler RL, Zhu K, Buchanan NS, Kreunin P, Kachman MT, Miller FR, Lubman D. 2004. A two-dimensional liquid-phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification. Proteomics 4:562-577.
19. He Y, Yeung ES, Chan KC, Issaq HJ. 2002. Two dimensional mapping of cancer cell extracts by liquid chromatography-capillary electrophoresis with ultraviolet absorbance detection. J Chromatogr A 979(1-2):81-89.
20. Hutchens TW, Yip TT. 1993. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun Mass Spectrom 7:576-580.
21. Hynes SO, McGuire J, Wadström T. 2003. Potential for proteomic profiling of Helicobacter pylori and other Helicobacter spp. using a ProteinChip array. FEMS Immunol Med Microbiol 36:151-158.
22. Imai K, Yamanaka H. 1998. The significance and limitation of prostate specific antigen in the mass screening for prostate cancer. Nippon Rinsho 56:1994-1997.
23. Issaq HJ, Chan KC, Liu CS, Li Q. 2001. Multidimensional high performance liquid chromatography-capillary electrophoresis separation of a protein digest: an update. Electrophoresis 22:1133-1135.
24. Issaq HJ, Conrads TP, Janini GM, Veenstra TD. 2002. Methods for fractionation, separation and profiling of proteins and peptides. Electrophoresis 23:3048-3061.
25. Issaq HJ, Conrads TP, Veenstra TD. 2003. Proteomic patterns: A potential test for early diagnosis of ovarian cancer. The Female Patient 28:42-52.
26. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, Woolas R, Jeyarajah AR, Sibley K, Lowe DG, Oram DH. 1999. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 353:1207-1210.
27. Janini GM, Chan KC, Conrads TP, Issaq HJ, Veenstra TD. 2004. Two-dimensional liquid chromatography-capillary zone electrophoresis-sheathless electrospray ionization-mass spectrometry: evaluation for peptide analysis and protein identification. Electrophoresis 25:1973-1980.
28. Johnston-Wilson NL, Bouton CMLS, Pevsner J, Breen JJ, Torrey EF, Yolken RH, The Stanley Neurovirology Working Group. 2001. Emerging technologies for large-scale screening of human tissues and fluids in the study of severe psychiatric disease. Int J Neuropsychopharm 4:83-92.
29. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF III. 2002. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2:76-84.
30. Kainz C. 1996. Early detection and preoperative diagnosis of ovarian carcinoma. Wien Med Wochenschr 146:2-7.
31. Kaiser T, Wittke S, Just I, Krebs R, Bartel S, Fliser D, Mischak H, Weissinger EM. 2004. Capillary electrophoresis coupled to mass spectrometer for automated and robust polypeptide determination in body fluids for clinical use. Electrophoresis 25:2044-2055.
32. Kaul M, Garden GA, Lipton SA. 2001. Pathways to neuronal injury and apoptosis in HIVassociated dementia. Nature 410:988-994.
33. Klose J, Kobalz U. 1995. Two dimensional electrophoresis of proteins. An updated protocol and implications for a functional analysis of the genome. Electrophoresis 16:1034-1059.
34. Koopman J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CT, Chan DW, Goggins M. 2004. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res 10:860-868.
35. Lagendijk JH, Mullink H, VanDeist PJ, Meijer GA, Meijer CJLM. 1998. Tracing the origin of adenocarcinomas with unknown primary using immunochemistry. Human Pathol 29:491-497.
36. Lai CC, Tsai CH, Tsai FJ, Lee CC, Lin WD. 2001. Rapid monitoring of congenital adrenal hyperplasia with microbore high-performance liquid chromatography/electrospray ionization tandem mass spectrometry from dried blood spots. Rapid Commun Mass Spectrom 15:2145-2151.
37. Lawrie LC, Curran S, McLeod HL, Fothergill JE, Murray GI. 2001. Application of laser capture microdissection and proteomics in colon cancer. Mol Pathol 54:253-258.
38. Lewczuk P, Esselmann H, Markus M, Wollscheid V, Neumann M, Otto M, Maler JM, Ruther E, Kornhuber J, Wiltfang J. 2003. The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer's disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun Mass Spectrom 17:1291-1296.
39. Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, Otto M, Kornhuber J, Wiltfang J. 2004. Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer's disease. Biol Psychiatry 55:524-530.
40. Li J, Zhang Z, Rosenzweig JM, Wang YY, Chan DW. 2002. Proteomics and bioinformatics to detect breast cancer. Clin Chem 48:1296-1304.
41. Li J, White N, Zhang Z, Rosenzweig J, Mangold LA, Partin AW, Chan DW. 2004. Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. J Urol 171:1782-1787.
42. Luo X, Carlson KA, Wojna V, Mayo R, Biskup TM, Stoner J, Anderson J, Gendelman HE, Melendez LM. 2003. Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. Neurology 60:1931-1937.
43. MacNeil JS. 2004. Better biomarkers for the diagnostics labyrinth. Genome Technol 24-33.
44. Martin SA, Rosenthal RS, Biemann K. 1987. Fast atom bombardment mass spectrometry and tandem mass spectrometry of biologically active peptidoglycan monomers from Neisseria gonorrhoeae. J Biol Chem 262:7514-7522.
45. McDonald WH, Yates JR III. 2002. Shotgun proteomics and biomarker discovery. Dis Markers 18:99-105.
46. National Cancer Institute News Center. 2004. Proteomics and Cancer. http://www.cancer.gov/newscenter/pressreleases/proteomicsQandA.
47. Neuhoff NV, Kaiser T, Wittke S, Krebs R, Pitt A, Burchard A, Sundmacher A, Schlegelberger B, Kolch W, Mischak H. 2004. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 18:149-156.
48. NIH. 2004. US Department of Health and Human Services, NIAID HIV/AIDS Statistics, 2004. http://www.niaid.nih.gov/factsheets/aidsstat.html.
49. Nishizuka S, Chen S-T, Gwadry FG, Alexander J, Major SM, Scherf U, Reinhold WC, Waltham M, Charboneau L, Young L, Bussey KJ, Kim S, Lababidi S, Lee JK, Pittaluga S, Scudiero DA, Sausville EA, Munson PJ, Petricoin EF III, Liotta LA, Hewitt SM, Raffeld M, Weinstein JN. 2003. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic and tissue array profiling. Cancer Res 63:5243-5250.
50. O'Farrell PH. 1975. High resolution two-dimensional electrophoresis of proteins. J Biol Chem 250:4007-4021.
51. Petricoin EF III, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. 2002a. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577.
52. Petricoin EF III, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. 2002b. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94:1576-1578.
53. Petricoin EF, Liotta LA. 2004. SELDI TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 15:24-30.
54. Pieper R, Su Q, Gatlin CL, Huang ST, Anderson NL, Steiner S. 2003. Multi-component immunoaffinity subtraction chromatography: an innovative step towards a comprehensive survey of the human plasma proteome. Proteomics 3:422-432.
55. Pusztai L, Gregory BW, Baggerly KA, Pang B, Koopman J, Kuerer HM, Esteva FJ, Symmons WF, Wagner P, Hortobagyi GN, Laronga C, Semmes OJ, Wright GL Jr, Drake RR, Vlahou A. 2004. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant chemotherapy for breast carcinoma. Cancer 100:1814-1822.
56. Rai AJ, Zhang Z, Rosenzweig J, Shih IM, Pham T, Fung ET, Sokoll LJ, Chan DW. 2002. Proteomic approaches to tumor marker discovery. Arch Pathol Lab Med 126:1518-1526.
57. Shihabi ZK, Konen JC, O'Connor ML. 1991. Albuminuria versus urinary total protein for detecting chronic renal disorders. Clin Chem 37:621-624.
58. Shiwa M, Nishimura Y, Wakatabe R, Fukawa A, Arikuni H, Ota H, Kato Y, Yamori T. 2003. Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. Biochem Biophys Res Commun 309:18-25.
59. Soldes OS, Kuick RD, Thompson IA II, Hughes SJ, Orringer MB, Iannettini MD, Hanash SM, Beer DG. 1999. Differential expression of Hsp27 in normal oesophageal, Barrett's metaplasia, and oesophageal adenocarcinomas. Br J Cancer 79:595-603.
60. Thulasiraman V, McCutchen-Maloney SL, Motin VL, Garcia E. 2001. Detection and identification of virulence factors in Yersinia pestis using SELDI ProteinChip System. Biotechniques 30:428-432.
61. Uchida T, Fukawa A, Uchida M, Fujita K, Saito K. 2002. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 1:495-499.
62. Van QN, Klose JR, Lucas DA, Prieto DA, Luke BT, Collin J, Burt SK, Chmurny GN, Issaq HJ, Conrads TP, Veenstra TD. 2003, 2004. The use of urine proteomic and metabonomic patterns for the diagnosis of interstitial cystitis and bacterial cystitis. Dis Markers 19:169-183.
63. Villanueva J, Philip J, Entenberg D, Chaparro CA, Tanwar MK, Holland EC. Tempst P. 2004. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. Anal Chem 76:1560-1570.
64. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright GL Jr. 2001. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158:1491-1502.
65. Voss T, Ahorn H, Haberl P, Dohner H, Wilgenbus K. 2001. Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int J Cancer 91:180-186.
66. Wadsworth JT, Somers KD, Cazares LH, Malik G, Adam BL, Stack BC Jr., Semmes OJ. 2004. Serum protein profiles to identify head and neck cancer. Clin Cancer Res 10:1625-1632.
67. Wagner M, Naik DN, Pothan A, Kasukurti S, Devineni RR, Adam BL, Semmes OJ, Wright GL Jr. 2004. Computational protein biomarker prediction: a case study for prostate cancer. BMC Bioinformatics 5:26.
68. Wang H, Kachman MT, Schwartz DR, Cho KR, Lubman DM. 2004. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: a strategy for identification of candidate cancer biomarkers. Proteomics 4:2476-2495.
69. Washburn MP, Wolters D, Yates JR. 2001. Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol 19:242-247.
70. Wauters CCAP, Smedts F, Gerrits LGM, Bosman FT, Ramaekers FCS. 1995. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Human Pathol 26:852-855.
71. Weissinger EM, Wittke S, Kaiser T, Haller H, Bartel S, Krebs R, Golovko I, Rupprecht HD, Haubitz M, Hecker H, Mischak H, Fliser D. 2004. Proteomic patterns established with capillary electrophoresis and mass spectrometry for diagnostic purposes. Kidney Int 265:2426-2434.
72. Wittke SH, Fliser D, Haubitz M, Bartel S, Krebs H, Hausadel F, Hillmann M, Golovko I, Koester P, Haller H, Kaiser T, Mischak H, Weissinger EM. 2003. Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A 1013:173-181.
73. Wojna V, Carlson KA, Luo X, Mayo R, Melendez LM, Kraiselburd E, Gendelman HE. 2004. Proteomic fingerprinting of human immunodeficiency virus type 1-associated dementia from patient monocyte-derived macrophages: a case study. J NeuroVir 10:74-81.
74. Wong YF, Cheung TH, Lo KW, Wang VW, Chan CS, Ng TB, Chung TK, Mok SC. 2004. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. Cancer Lett 211:227-234.
75. Wright GL, Cazarres LH, Leung S-M, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A. 1999. ProteinChip surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 2:264-276.
76. Wu S-L, Hancock WS, Goodrich GG, Kunitake ST. 2003. An approach to the proteomic analysis of a breast cancer cell line (SKBR-3). Proteomics 3:1037-1046.
77. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF III. 2001. New approaches to proteomic analysis of breast cancer. Proteomics 1:1205-1215.
78. Xiao Z, Adam BL, Cazares LH, Clements MA, Davis JW, Schellhammer PF, Dalmasso EA, Wright GL Jr. 2001. Quantitation of serum prostate-specific antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease. Cancer Res 61:6029-6033.
79. Xiao X, Liu D, Tang Y, Guo F, Xia L, Liu J, He D. 2003. Development of proteomic patterns for detecting lung cancer. Dis Markers 19:33-39.
80. Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Phillips RKS, Patterson S, Conrads TP, Veenstra TD, Greenwald P, Hawk ET, Ali IU. 2004. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 64:1-6.
81. Yanagisawa K, Shyr Y, Xu BJ, Massion PP, Larsen PH, White BC, Roberts JR, Edgerton M, Gonzalez A, Nadaf S, Moore JH, Caprioli RM, Carbone DP. 2003. Proteomic patterns of tumor subsets in non-small-cell lung cancer. Lancet 362:433-439.
82. Yang ECC, Guo J, Diehl G, DeSouza L, Rodrigues MJ, Romaschin AD, Colgan TJ, Siu KWM. 2004. Protein expression profiling of endometrial malignancies reveals a new tumor marker: chaperonin 10. J Proteome Res 3:636-643.
83. Yashikawa Y, Mukai H, Hino F, Asada K, Kato I. 2000. Isolation of two novel genes downregulated in gastric cancer. Jpn J Cancer Res 91:459-463.
84. Yeo CT, Cameron JL, Lillemoe KD, Sitzman JV. 1995. Pancreatic duodenectomy for cancer of the head of the pancreas. Ann Surg 221:721-731.
85. Zhang L, Yu W, He T, Yu J, Caffrey RE, Dalmasso EA, Fu S, Pham T, Mei J, Ho JJ, Zhang W, Lopez P, Ho DD. 2002. Contribution of human alpha-defensin 1, 2, and 3 to the anti-HIV-1 activity of CD8 antiviral factor. Science 298:995-1000.
86. Zhang Z, Bast RC Jr, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wanf YY, Meng X-Y, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HWA, van der Zee AGJ, Jacobs JI, Fung ET. 2004. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 64:5882-5890.
87. Zheng J, Gendelman HE. 1997. The HIV-1 associated dementia complex: a metabolic encephalopathy fueled by viral replication in mononuclear phagocytes. Curr Opin Neurol 10:319-325.
88. Zhukov TA, Johnson RA, Cantor AB, Clark RA, Jockman MS. 2003. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 40:267-279.